Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.

Abstract

We have studied the pharmacokinetics of desferrioxamine (DFA), ferrioxamine (FeA) and aluminoxamine (AlA) in patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) after 10 mg/kg (15.24 mumol/kg) body weight desferrioxamine (DESFERAL) administration by intramuscular and intraperitoneal routes. The results show an easy exchange of DFA between the plasma and the peritoneal fluid regulated by the relative concentrations of DFA in the two compartments. When the equilibrium is reached, the concentration of DFA are approximately the same in the plasma and the peritoneal fluid.

• Authors: P Allain, D Chaleil, Y Mauras, M C Varin, K S Ang, G Cam, P Simon
• Journal: Clinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 173 Issue 3 Pg. 313-6 (Apr 29 1988) ISSN: 0009-8981 [Print] Netherlands
• PMID: 3383431 (Publication Type: Journal Article)

Chemical References

• Chelating Agents
• Aluminum
• Iron
• Deferoxamine

Topics

• Aged
• Aged, 80 and over
• Aluminum (pharmacokinetics)
• Chelating Agents (pharmacokinetics)
• Deferoxamine (pharmacokinetics)
• Humans
• Iron (pharmacokinetics)
• Kidney Failure, Chronic (metabolism, therapy)
• Male
• Peritoneal Dialysis, Continuous Ambulatory